Key result
SGLT2 inhibitors linked to ~22% fewer heart failure hospitalizations in stage 5 CKD.
Why the study?
Evidence supporting SGLT2 inhibitor use in stage 5 CKD remains limited because major randomized trials have largely excluded this population.
Do SGLT2 inhibitors reduce cardiovascular and kidney outcomes in patients with stage 5 chronic kidney disease?
Meta-Analysis (n=57,156)
Do SGLT2 inhibitors reduce cardiovascular and kidney outcomes in patients with stage 5 chronic kidney disease?
This systematic review and meta-analysis of observational studies suggests that SGLT2 inhibitors are associated with lower rates of heart failure hospitalization in patients with stage 5 CKD, supporting the need for dedicated randomized trials in this population.
Answers are grounded in this paper and cite their sources.
May inform SGLT2 inhibitor decisions in stage 5 CKD; leaves open confirmation of benefits and safety in randomized trials.
**Background:** Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because major randomized trials have largely excluded this population. We evaluated associations between SGLT2 inhibitor use and cardiovascular and kidney outcomes in patients with stage 5 CKD. **Methods:** We systematically searched PubMed, Scopus, Cochrane CENTRAL, and Google Scholar through April 10, 2026. Studies comparing SGLT2 inhibitors with nonuse or other glucose-lowering therapies were eligible. Hazard ratios (HRs) were pooled using random-effects models, and risk of bias was assessed using ROBINS-I. Certainty of evidence was assessed using GRADE. **Results:** Five observational cohorts met inclusion criteria, of which three contributed to the meta-analysis, comprising 57,156 participants, including 28,559 SGLT2 inhibitor users. SGLT2 inhibitor use was associated with fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72-0.85) and acute myocardial infarctions (HR 0.64; 95% CI 0.56-0.72). Associations with all-cause mortality (HR 0.84; 95% CI 0.58-1.21) and dialysis initiation (HR 0.63; 95% CI 0.30-1.33) were not statistically significant. In analyses restricted to treatment-initiation cohorts, the association with fewer heart failure hospitalizations persisted, whereas the myocardial infarction association was no longer significant. Certainty of evidence was low or very low across outcomes. **Conclusions:** Observational evidence suggests potential cardiovascular benefits of SGLT2 inhibitors in stage 5 CKD, particularly fewer heart failure hospitalizations. Effects on mortality, dialysis initiation, and myocardial infarction remain uncertain. Dedicated randomized trials are needed to establish efficacy and safety in this population.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a meta-analysis in Stage 5 chronic kidney disease (n=57,156). SGLT2 inhibitors vs. Nonuse or other glucose-lowering therapies was evaluated on Heart failure hospitalizations (HR 0.78, 95% CI 0.72-0.85). SGLT2 inhibitor use in stage 5 CKD was associated with fewer heart failure hospitalizations and acute myocardial infarctions.
Synapse has enriched 10 related papers. Consider them for comparative context: